早期低级别子宫内膜癌伴恶性腹腔细胞学激素治疗或化疗的比较效果研究
基于美国国家癌症数据库2010至2017年2730例Ⅰ期1-2级子宫内膜样癌伴恶性腹腔细胞学患者,比较术后激素治疗(112例)、化疗(348例)与无辅助全身治疗(2270例)的趋势与总生存。激素治疗和无辅助全身治疗使用增加而化疗减少(P=0.04);激素治疗与化疗均与总生存无显著关联。
要点
- 激素治疗使用从2.7%升至4.5%,无辅助全身治疗从81.8%升至84.4%,化疗从15.5%降至11.1%(P=0.04)。
- 激素治疗相比化疗与更年长、更近诊断年份、1级病变、学术机构治疗等相关(P<0.05)。
- 激素治疗(aHR 0.61,95%CI 0.27-1.40)和化疗(aHR 1.33,95%CI 0.92-1.93)与无辅助全身治疗相比均与总生存无显著关联。
核心结论
- 早期低级别子宫内膜癌伴恶性腹腔细胞学患者中,激素治疗使用增加而化疗使用减少,两种辅助治疗与无辅助全身治疗相比均与短期总生存无显著关联。
研究设计与样本
- 比较效果研究,查询美国国家癌症数据库2010至2017年数据,纳入2730例Ⅰ期1-2级子宫内膜样癌伴恶性腹腔细胞学患者。
- 按术后治疗分为化疗组(n=348,12.7%)、激素治疗组(n=112,4.1%)和无辅助全身治疗组(n=2270,83.2%)。
- 采用多变量logistic回归分析辅助治疗相关趋势与特征,多变量Cox比例风险回归分析总生存。
主要发现
- 激素治疗使用从2.7%升至4.5%,无辅助全身治疗从81.8%升至84.4%,化疗使用从15.5%降至11.1%(P=0.04)。
- 多变量分析中,激素治疗相比化疗与更年长、更近诊断年份、1级病变、学术/研究机构治疗、微创手术、无淋巴血管间隙浸润及未接受放疗相关(P<0.05)。
- 激素治疗(aHR 0.61,95%CI 0.27-1.40)和化疗(aHR 1.33,95%CI 0.92-1.93)与无辅助全身治疗相比均与总生存无显著关联。
- 低危组(ⅠA期、1-2级肿瘤、无淋巴血管间隙浸润;n=1453)中69例(4.7%)接受激素治疗,117例(8.1%)接受化疗,三组总生存相似(P=0.89)。
关键数值与推荐
- 激素治疗使用从2.7%升至4.5%,无辅助全身治疗从81.8%升至84.4%,化疗使用从15.5%降至11.1%(P=0.04)。
- 激素治疗与总生存:aHR 0.61,95%CI 0.27-1.40(以无辅助全身治疗为参照)。
- 化疗与总生存:aHR 1.33,95%CI 0.92-1.93(以无辅助全身治疗为参照)。
- 低危组三组总生存相似(P=0.89),其中激素治疗69例(4.7%),化疗117例(8.1%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine trends, characteristics, and outcomes related to hormonal therapy (HT) or chemotherapy (CT) use for early-stage, low-grade endometrial cancer with malignant peritoneal cytology (MPC). METHODS: This is a comparative effectiveness study querying the National Cancer Database from 2010 to 2017. Study population was 2730 women with stage I grade 1-2 endometrioid endometrial cancer who had MPC at primary hysterectomy. Patients were stratified based on postoperative therapy as: CT (n = 348, 12.7%), HT (n = 112, 4.1%), and neither two (n = 2270, 83.2%). Outcome measures included (i) trends and characteristics related to adjuvant therapy, assessed with a multivariable logistic regression model, and (ii) overall survival (OS) assessed with a multivariable Cox proportional hazards regression model. RESULTS: The number of women who received HT (2.7% to 4.5%) or no adjuvant systemic therapy (81.8% to 84.4%) increased while CT use decreased (15.5% to 11.1%)(P = 0.04). In a multivariable analysis, HT use was associated with older age, more recent year of diagnosis, grade 1 lesions, treatment at academic/research facilities, performance of minimally invasive surgery, no lympho-vascular space invasion, and absence of radiotherapy compared to CT use (P < 0.05). Neither HT (adjusted-hazard ratio [aHR] 0.61, 95% confidence interval [CI] 0.27-1.40) nor CT (aHR 1.33, 95% CI 0.92-1.93) were associated with OS compared to no adjuvant systemic therapy. In the low-risk group (stage IA, grade 1-2 tumors, and no lympho-vascular space invasion; n = 1453), 69 (4.7%) women received HT and 117 (8.1%) received CT. OS was similar across the three groups (P = 0.89). CONCLUSION: There was an increasing utilization of HT and decreasing utilization of CT as adjuvant therapy for early-stage, low-grade endometrial cancer with MPC. These two adjuvant therapies were not associated with short-term OS compared to neither two.
引用
- Matsuo K, Chen L, Guo XM, et al. Hormonal therapy or chemotherapy for early-stage, low-grade endometrial cancer with malignant peritoneal cytology: A comparative effectiveness study. Gynecol Oncol. 2022. PMID: 35227514. doi:10.1016/j.ygyno.2022.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。